Xponance Inc. Has $63.94 Million Holdings in AbbVie Inc. (NYSE:ABBV)

Xponance Inc. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 412,600 shares of the company’s stock after purchasing an additional 7,001 shares during the quarter. AbbVie makes up about 0.8% of Xponance Inc.’s portfolio, making the stock its 18th largest holding. Xponance Inc.’s holdings in AbbVie were worth $63,941,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Hibernia Wealth Partners LLC bought a new position in AbbVie during the third quarter worth $36,000. PCA Investment Advisory Services Inc. bought a new position in shares of AbbVie during the second quarter valued at about $38,000. True Wealth Design LLC bought a new position in shares of AbbVie during the fourth quarter valued at about $39,000. Blue Bell Private Wealth Management LLC lifted its position in shares of AbbVie by 39.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 286 shares of the company’s stock valued at $43,000 after purchasing an additional 81 shares in the last quarter. Finally, Horrell Capital Management Inc. bought a new position in shares of AbbVie during the third quarter valued at about $45,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

AbbVie Trading Up 0.2 %

Shares of NYSE ABBV traded up $0.41 during mid-day trading on Thursday, hitting $164.66. The stock had a trading volume of 4,479,334 shares, compared to its average volume of 5,621,431. The company has a debt-to-equity ratio of 5.02, a quick ratio of 0.76 and a current ratio of 0.87. The business has a 50 day moving average price of $175.79 and a two-hundred day moving average price of $159.94. The firm has a market cap of $291.56 billion, a P/E ratio of 60.89, a price-to-earnings-growth ratio of 2.09 and a beta of 0.58. AbbVie Inc. has a 1 year low of $130.96 and a 1 year high of $182.89.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, February 2nd. The company reported $2.79 earnings per share for the quarter, topping analysts’ consensus estimates of $2.76 by $0.03. The firm had revenue of $14.30 billion for the quarter, compared to the consensus estimate of $14.02 billion. AbbVie had a net margin of 8.95% and a return on equity of 162.28%. The company’s revenue was down 5.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.60 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 11.17 EPS for the current fiscal year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 15th. Stockholders of record on Monday, April 15th will be given a $1.55 dividend. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.77%. The ex-dividend date of this dividend is Friday, April 12th. AbbVie’s dividend payout ratio is presently 227.11%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ABBV shares. Barclays raised their price target on shares of AbbVie from $185.00 to $195.00 and gave the company an “overweight” rating in a research report on Wednesday, March 27th. Guggenheim raised their price objective on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a report on Friday, March 22nd. William Blair upgraded shares of AbbVie from a “market perform” rating to an “outperform” rating in a report on Monday, January 29th. Truist Financial lifted their target price on shares of AbbVie from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, February 6th. Finally, Raymond James lifted their target price on shares of AbbVie from $181.00 to $189.00 and gave the stock an “outperform” rating in a research note on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus price target of $177.43.

Insider Transactions at AbbVie

In other news, EVP Nicholas Donoghoe sold 21,082 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total value of $3,716,756.60. Following the sale, the executive vice president now directly owns 55,903 shares of the company’s stock, valued at approximately $9,855,698.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other AbbVie news, EVP Nicholas Donoghoe sold 21,082 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $176.30, for a total transaction of $3,716,756.60. Following the completion of the sale, the executive vice president now directly owns 55,903 shares in the company, valued at approximately $9,855,698.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Richard A. Gonzalez sold 138,616 shares of the firm’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $177.27, for a total transaction of $24,572,458.32. Following the sale, the chief executive officer now owns 519,099 shares of the company’s stock, valued at $92,020,679.73. The disclosure for this sale can be found here. Insiders have sold 383,324 shares of company stock valued at $67,780,003 in the last three months. 0.25% of the stock is currently owned by company insiders.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.